After the demonstration of the anti-tumor effect C29, we aimed to evaluate the efficacy of a CXCR1/2 inhibitor in preclinical model of HNSCC as early as possible after the onset of treatment using 18F-FDG PET-CT. The gene discussed is CXCR1; the disease is neoplasm.